The Asia-Pacific Region Builds the Infrastructure to Deliver Tomorrow’s Cures
The first time a physician infuses a patient with genetically modified T-cells engineered to target and destroy cancer, the act feels like medicine from the future. CAR-T cell therapy — chimeric antigen receptor T-cell therapy — is not a drug in any conventional sense. It is a living pharmaceutical, personalised to a specific patient, manufactured in a complex bioreactor process that transforms ordinary immune cells into precision oncological weapons. The therapy works. For certain blood cancers, it has produced responses in patients who had exhausted all other options. The problem, until recently, was that making it required infrastructure concentrated almost entirely in the United States and Western Europe.
The Asia-Pacific region is now systematically dismantling that geographic monopoly. The APAC cell and gene therapy (CGT) market is projected to reach USD 4 billion by 2027, and for CAR-T alone, the region has registered an estimated compound annual growth rate of 56 percent over the five-year period to 2026 — nearly one and a half times the global CAGR of 39 percent. Behind these numbers is a deliberate infrastructure buildout that is beginning to transform who can access these therapies and at what cost.
China has led the region in sheer volume, with over ten domestically developed CAR-T products receiving regulatory approval, often at dramatically lower prices than their Western counterparts. The competitive Chinese market has driven a compression in therapy pricing that is accelerating across the region. India reached its own milestone with the approval of NexCAR19, developed by ImmunoACT and IIT Bombay, as the country’s first domestically developed CD19 CAR-T product, priced at approximately USD 45,000 — a fraction of the USD 400,000-plus cost of equivalent Western therapies and a demonstration that local development can make transformative medicine accessible in lower-income settings.
The manufacturing challenge is where APAC’s ambitions meet their most demanding test. CAR-T production requires GMP-certified cleanrooms, closed-system single-use bioreactors, cryogenic logistics chains for storing and transporting live cell products, and highly trained technical staff capable of managing processes that combine molecular biology, immunology, and precision bioprocess engineering. Building and certifying such infrastructure takes years and requires capital investment that most clinical centres in the region cannot independently sustain.
The response has been a constellation of CDMOs (contract development and manufacturing organisations) and public-private partnerships. Thailand-based Genepeutic Bio, working with Cytiva’sFlexFactory biomanufacturing platform, established the first GMP-certified CAR-T manufacturing facility in Southeast Asia. Australia’s BioCina has entered a partnership with the University of Adelaide and Cytiva to create domestic manufacturing capacity for clinical programmes that previously required outsourcing to the US or Europe. Singapore, with its risk-based regulatory model and government-backed biomanufacturing hubs, has positioned itself as the regional CGT manufacturing governance centre.
The regulatory landscape across APAC remains complex and heterogeneous. Japan operates time-limited conditional approval pathways for regenerative medicine products. Singapore uses an adaptive risk-based model. China has a priority review channel. India’s CDSCO has developed specific guidelines for cellular and gene therapy products. This regulatory fragmentation increases the compliance burden for companies seeking multi-market access, but it has not impeded the region’s overall momentum — it has simply created a more stratified market where regulatory sophistication correlates with market maturity.
Beyond CAR-T, the broader CGT frontier in APAC encompasses gene therapy for rare genetic disorders, iPSC-derived cell therapies offering scalable ‘off-the-shelf’ alternatives to autologous manufacturing, and viral vector production for gene delivery. Cartherics, an Australian biotechnology company developing iPSC-derived NK cell therapies for ovarian cancer and endometriosis, was recognised as the most promising iPSC therapy pipeline in APAC at the 2025 Asia Pacific Cell and Gene Therapy Excellence Awards — a signal of the region’s advancing scientific ambition beyond conventional platforms.
The ultimate measure of APAC’s success in this domain will not be the number of approvals or the scale of investment. It will be the number of patients who receive these therapies at prices that do not require them to liquidate their life savings. India’s NexCAR19 at USD 45,000 demonstrates that localisation of the manufacturing and development value chain can translate directly into patient access. If the region can sustain that logic at scale, APAC will not merely be a participant in the cell and gene therapy revolution — it will redefine its terms.
– Dr. Kanaka Durga Chandu
